Table 4.

Evolution of visual impairment according to the aetiology and disease outcome

	Cohort (n=147)	JIA+ANA (n=58)	JIA−ANA (n=24)	ERA (n=9)	Idiopathic uveitis (n=36)	Sarcoidosis (n=9)	Others uveitis (n=11)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Irreversible impairement
Legal blindness (LogMAR=1), monocular blindness and LogMAR between 0.9 and 0.4 in fellow eye	8 (5)	3 (5)	2 (8)	0	1 (3)	1 (11)	1 (9)
Isolated monocular blindness	9 (6)	2 (3)	3 (13)	1 (11)	2 (5.5)	0	2 (18)
Visual impairment, both eyes (LogMAR between 0.9 and 0.4)	8 (5)	3 (5)	1 (4)	0	2 (5.5)	1 (11)	2 (18)
Visual impairment, one eye (LogMAR between 0.9 and 0.4)	6 (4)	3 (5)	0	0	3 (8.3)	0	0
Transient loss
Legal blondness	0	0	0	0	0	0	0
Visual impairment, both eyes (LogMAR between 0.9 and 0.4)	6 (4)	2 (3)	0	0	3 (8.3)	0	1 (9)
Visual impairment, one eye (LogMAR between 0.9 and 0.4)	8 (5)	1 (1.5)	1 (14)	2 (22)	3 (8.3)	0	1 (9)
Total
Overall	45 (30)	14 (24)	7 (38)	3 (33)	14 (38)	2 (22)	7 (63)
Long-term loss	31 (21)	11 (19)	6 (25)	1 (11)	8 (22)	2 (22)	5 (45)
Transient loss	14 (10)	3 (5)	1 (4)	2 (22)	6 (16)		2 (16)

ANA, antinuclear antibody; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis.